TY - JOUR
T1 - Neurochemical correlates of behavioral sensitization following repeated apomorphine treatment
T2 - Assessment of the role of D1 dopamine receptor stimulation
AU - Rowlett, James K.
AU - Mattingly, Bruce A.
AU - Bardo, Michael T.
PY - 1993/6
Y1 - 1993/6
N2 - Previous research has revealed a role of repeated D1 dopamine receptor stimulation in the development of behavioral sensitization to the D1/D2 agonist apomorphine. The present experiments assessed the role of repeated D1 receptor stimulation in neurochemical changes accompanying locomotor sensitization to apomorphine. To assess direct effects of D1 stimulation on dopamine synthesis, rats were injected with the D1 agonist SKF 38393 (8 mg/kg), followed by an injection with the 3,4‐dihydroxyphenylalanine (DOPA) decarboxylase inhibitor, NSD‐1015. DOPA accumulation, assessed in striatal, nucleus accumbens‐olfactory tubercle (NAOT), and ventral mesencephalon (VM) tissue samples, was not affected by acute SKF 38393. In the second experiment, rats were treated with 10 daily injections of vehicle, apomorphine (5 mg/kg) or the D1 agonist SKF 38393 (8 or 16 mg/kg). Daily measures of locomotor activity demonstrated a progressive increase in the apomorphine‐treated rats, but not the SKF 38393‐treated rats, across the 10 days. On day 11, all rats were injected with NSD‐1015 for measurement of DOPA accumulation. Dopamine synthesis was enhanced in the striatum after repeated apomorphine treatment. In contrast, repeated SKF 38393 treatment resulted in either a small decrease or no change in DOPA accumulation in the different brain regions (striatum, NAOT, VM). In the third experiment, tissue levels of dopamine, 3,4‐dihydroxyphenylacetic acid (DOPAC) and [3H]SCH 23390 binding to D1 receptors were measured in rats treated with 10 daily injections of vehicle, apomorphine (5 mg/kg), or SKF 38393 (16 mg/kg). In the striatum and NAOT, none of the repeated drug treatments had an effect on DOPAC or dopamine levels. In the VM, DOPAC levels were enhanced following repeated apomorphine, but not repeated SKF 38393, whereas dopamine levels were not affected by either drug treatment. D1 binding was not altered by the repeated drug treatments. Since repeated D1 stimulation by SKF 38393 did not produce the same alterations in dopamine synthesis and DOPAC levels as repeated apomorphine, the neurochemical effects accompanying locomotor sensitization to apomorphine probably are not mediated by D1 receptors. © 1993 Wiley‐Liss, Inc.
AB - Previous research has revealed a role of repeated D1 dopamine receptor stimulation in the development of behavioral sensitization to the D1/D2 agonist apomorphine. The present experiments assessed the role of repeated D1 receptor stimulation in neurochemical changes accompanying locomotor sensitization to apomorphine. To assess direct effects of D1 stimulation on dopamine synthesis, rats were injected with the D1 agonist SKF 38393 (8 mg/kg), followed by an injection with the 3,4‐dihydroxyphenylalanine (DOPA) decarboxylase inhibitor, NSD‐1015. DOPA accumulation, assessed in striatal, nucleus accumbens‐olfactory tubercle (NAOT), and ventral mesencephalon (VM) tissue samples, was not affected by acute SKF 38393. In the second experiment, rats were treated with 10 daily injections of vehicle, apomorphine (5 mg/kg) or the D1 agonist SKF 38393 (8 or 16 mg/kg). Daily measures of locomotor activity demonstrated a progressive increase in the apomorphine‐treated rats, but not the SKF 38393‐treated rats, across the 10 days. On day 11, all rats were injected with NSD‐1015 for measurement of DOPA accumulation. Dopamine synthesis was enhanced in the striatum after repeated apomorphine treatment. In contrast, repeated SKF 38393 treatment resulted in either a small decrease or no change in DOPA accumulation in the different brain regions (striatum, NAOT, VM). In the third experiment, tissue levels of dopamine, 3,4‐dihydroxyphenylacetic acid (DOPAC) and [3H]SCH 23390 binding to D1 receptors were measured in rats treated with 10 daily injections of vehicle, apomorphine (5 mg/kg), or SKF 38393 (16 mg/kg). In the striatum and NAOT, none of the repeated drug treatments had an effect on DOPAC or dopamine levels. In the VM, DOPAC levels were enhanced following repeated apomorphine, but not repeated SKF 38393, whereas dopamine levels were not affected by either drug treatment. D1 binding was not altered by the repeated drug treatments. Since repeated D1 stimulation by SKF 38393 did not produce the same alterations in dopamine synthesis and DOPAC levels as repeated apomorphine, the neurochemical effects accompanying locomotor sensitization to apomorphine probably are not mediated by D1 receptors. © 1993 Wiley‐Liss, Inc.
KW - 3,4‐Dihydroxyphenylacetic acid (DOPAC)
KW - 3,4‐Dihydroxyphenylalanine (DOPA)
KW - Locomotor activity
KW - Mesolimbic pathway
KW - Nigrostriatal pathway
KW - SKF 38393
KW - [H]SCH 23390
UR - http://www.scopus.com/inward/record.url?scp=0027212473&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027212473&partnerID=8YFLogxK
U2 - 10.1002/syn.890140209
DO - 10.1002/syn.890140209
M3 - Article
C2 - 8332946
AN - SCOPUS:0027212473
SN - 0887-4476
VL - 14
SP - 160
EP - 168
JO - Synapse
JF - Synapse
IS - 2
ER -